Cassava Sciences announces name change to Filana Therapeutics

Cassava Sciences (SAVA) announced the rebranding of the Company, with a name change to Filana Therapeutics (FLNA). The new name and corporate brand reflect the Company’s strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, such as Tuberous Sclerosis Complex-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. The Company will begin trading under the new ticker symbol “FLNA” on the Nasdaq Capital Market at the open of the market on March 11, 2026. “The launch of Filana Therapeutics represents a new beginning for our Company. Growing evidence suggests that filamin A is an important regulator of neuronal development and that modulating filamin A may provide a new approach to treating CNS disorders such as TSC-related epilepsy. Centering our identity on filamin A reflects our dedication to rigorous scientific discovery and to bringing new treatment options to patients and their families,” said Rick Barry, CEO.